Dale Conaway
Director/Board Member at BIOXYTRAN, INC.
Net worth: 126 376 $ as of 2024-04-29
Dale Conaway active positions
Companies | Position | Start | End |
---|---|---|---|
BIOXYTRAN, INC. | Director/Board Member | 2018-11-01 | - |
Independent Dir/Board Member | 2018-11-01 | - | |
Office of Research Oversight | Chief Tech/Sci/R&D Officer | - | - |
Career history of Dale Conaway
Former positions of Dale Conaway
Companies | Position | Start | End |
---|---|---|---|
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Director/Board Member | - | 2018-08-02 |
Independent Dir/Board Member | - | 2018-08-02 | |
NANOMIX CORPORATION | Director/Board Member | 2009-08-31 | 2016-09-14 |
Independent Dir/Board Member | 2012-03-25 | 2016-09-14 | |
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Director/Board Member | 2010-02-09 | 2010-11-29 |
GALECTIN THERAPEUTICS INC. | Director/Board Member | 2001-04-30 | 2009-02-11 |
Federal Research, Inc. | Corporate Officer/Principal | 2000-12-31 | 2006-01-01 |
BioXyTran, Inc. /Old/
BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Director/Board Member | 1997-12-31 | 2001-01-31 |
Michigan Department of Agriculture | Corporate Officer/Principal | 1997-12-31 | 2000-12-31 |
Training of Dale Conaway
Michigan State University | Graduate Degree |
Tuskegee University | Doctorate Degree |
Statistics
International
United States | 12 |
Operational
Director/Board Member | 6 |
Independent Dir/Board Member | 3 |
Corporate Officer/Principal | 2 |
Sectoral
Health Technology | 7 |
Consumer Services | 3 |
Government | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
GALECTIN THERAPEUTICS INC. | Health Technology |
BIOXYTRAN, INC. | Health Technology |
Private companies | 7 |
---|---|
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Health Technology |
Michigan Department of Agriculture | Government |
Boston Therapeutics, Inc.
Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
Office of Research Oversight | |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Health Technology |
BioXyTran, Inc. /Old/
BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Health Technology |
Federal Research, Inc. |
- Stock Market
- Insiders
- Dale Conaway
- Experience